The ALLG is an Australian not-for-profit, public unlisted company limited by guarantee and is a registered charity.

ALLG Board of Management

The ALLG is governed on behalf of members by a Board of Management in accordance with the ALLG Constitution. Subject to the exercise by the Board of the powers contained in the ALLG Constitution, the Board manages the company and directs the affairs of the company. Current Board members are:

Peter T. Kempen

AM, FCA, FAICD
Chairman of the Board

Peter was appointed to the Board as a Director and Chairman in early 2010. He is a member of the Finance and Audit Committee of the Board.

Associate Professor

Peter Mollee

MBBS(Hons), MMedSc, FRACP, FRCPA
Director

Peter has been an active member of the Scientific Advisory Committee (SAC) since 2012. He was appointed as the Chairman of the SAC in November 2017.

Geraldine Gray

BA, LLB, LLM
Director

Geraldine was appointed to the Board as a Director in early 2010. She is a member of the Marketing Committee of the Board.

Lisa Keenan

Bachelor of Commerce, Chartered Management Accountant and Post Graduate Diploma of Applied Finance
Director

Lisa Keenan was elected as a Director of the ALLG in October 2020.

Malcolm McComas

BEc, LLB, SF Fin, FAICD
Director

Malcolm was elected to the Board, and has performed the role of Chairman of the Finance and Audit Committee of the Board, since May 2010.

Tina Rankovic

Dip Diag Rad (Sturt CAE), Grad Dip Mgmt (RMIT), MBus (Swinburne)
Director

Tina was elected to the ALLG Board as a Director in early 2013 with aims to embed fund-raising as a core operational activity utilising her skills, experience and networks.

Professor

Andrew Roberts

MBBS, PhD, FRACP, FRCPA
Director

Andrew has been a Director with the ALLG Board since 2010, and has served on several other not-for-profit boards.

Professor

Philip Rowlings

MBBS, FRACP, FRCPA, MS
Director

Phil was elected to the Board as a Director in October 2016. He has over 30 years research experience in clinical trials of new treatments, biostatistical analyses of large datasets in blood and marrow transplant for leukaemia, multiple myeloma, lymphoma and other malignancies.

Professor

Peter Browett

BMedSci, MBChB, FRACP, FRCPA
Director

Peter has been an active member of the Company since April 1997. He currently chairs the Safety and Data Monitoring Committee (SDMC).